Shi Han Wei
Directeur/Membre du Conseil chez Beijing Xiangxin Biotechnology Co., Ltd.
Profil
Shi Han Wei is currently the Director at Beijing Xiangxin Biotechnology Co., Ltd.
and Beijing Meizhong Airui Cancer Hospital Co., Ltd.
He previously worked as a Director at Beijing Amcare Medical Management Co., Ltd.
Postes actifs de Shi Han Wei
| Sociétés | Poste | Début |
|---|---|---|
Beijing Xiangxin Biotechnology Co., Ltd.
 Beijing Xiangxin Biotechnology Co., Ltd. BiotechnologyHealth Technology Beijing Xiangxin Biotechnology Co., Ltd. was founded in 2018 and is based in the economic-technological development area. The Chinese company has established two R & D centers covering a total area of 5,000 square meters. The company provides comprehensive solutions for cancer precision medicine using genomics technologies, with a focus on next-generation sequencing (NGS) in solid tumors and hematological malignancies. Acornmed has launched over 30 clinical testing products covering early detection and screening of multiple cancers, hereditary cancer identification, companion diagnostics for targeted therapy and immunotherapy, prognostic stratification, longitudinal monitoring of tumors, etc. The company has served more than 500 hospitals and have been endorsed by many clinical oncologists and laboratory professionals. | Directeur/Membre du Conseil | 13/11/2019 |
Beijing Meizhong Airui Cancer Hospital Co., Ltd.
 Beijing Meizhong Airui Cancer Hospital Co., Ltd. Hospital/Nursing ManagementHealth Services Beijing Meizhong Airui Cancer Hospital Co., Ltd. is a third-level tumor specialist consultation hospital founded in 2017. The company is based in Beijing, China. The hospital offers a variety of tumor expert consultations and has eight major clinic centers, including lung cancer, breast, gynecological tumor, gastrointestinal tumor, hepatobiliary tumor, urinary tumor, tumor consultation, and tumor sieve recovery. Additionally, the hospital has multiple medical technical departments such as tumor radiation images, tumor pathology, tumor radiotherapy, tumor ultrasound, and tumor early screen intervention inspection. | Directeur/Membre du Conseil | 09/04/2020 |
Anciens postes connus de Shi Han Wei
| Sociétés | Poste | Fin |
|---|---|---|
Beijing Amcare Medical Management Co., Ltd.
 Beijing Amcare Medical Management Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Beijing Amcare Medical Management Co., Ltd. engages in the sale of medical devices and provision of medical services. Its business activities include medical management consulting, medical technology development, technology consulting, and sale of daily necessities, packaging materials, chemical products, and building materials. The company was founded on October 22, 2012 and is headquartered in Beijing, China. | Directeur/Membre du Conseil | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Beijing Amcare Medical Management Co., Ltd.
Beijing Amcare Medical Management Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Beijing Amcare Medical Management Co., Ltd. engages in the sale of medical devices and provision of medical services. Its business activities include medical management consulting, medical technology development, technology consulting, and sale of daily necessities, packaging materials, chemical products, and building materials. The company was founded on October 22, 2012 and is headquartered in Beijing, China. | Commercial Services |
Beijing Xiangxin Biotechnology Co., Ltd.
Beijing Xiangxin Biotechnology Co., Ltd. BiotechnologyHealth Technology Beijing Xiangxin Biotechnology Co., Ltd. was founded in 2018 and is based in the economic-technological development area. The Chinese company has established two R & D centers covering a total area of 5,000 square meters. The company provides comprehensive solutions for cancer precision medicine using genomics technologies, with a focus on next-generation sequencing (NGS) in solid tumors and hematological malignancies. Acornmed has launched over 30 clinical testing products covering early detection and screening of multiple cancers, hereditary cancer identification, companion diagnostics for targeted therapy and immunotherapy, prognostic stratification, longitudinal monitoring of tumors, etc. The company has served more than 500 hospitals and have been endorsed by many clinical oncologists and laboratory professionals. | Health Technology |
Beijing Meizhong Airui Cancer Hospital Co., Ltd.
Beijing Meizhong Airui Cancer Hospital Co., Ltd. Hospital/Nursing ManagementHealth Services Beijing Meizhong Airui Cancer Hospital Co., Ltd. is a third-level tumor specialist consultation hospital founded in 2017. The company is based in Beijing, China. The hospital offers a variety of tumor expert consultations and has eight major clinic centers, including lung cancer, breast, gynecological tumor, gastrointestinal tumor, hepatobiliary tumor, urinary tumor, tumor consultation, and tumor sieve recovery. Additionally, the hospital has multiple medical technical departments such as tumor radiation images, tumor pathology, tumor radiotherapy, tumor ultrasound, and tumor early screen intervention inspection. | Health Services |
